Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

I am unlikely to upgrade the stock just yet. The most recent fundamental data that we have regarding Eli Lilly covers the final quarter of the company's 2024 fiscal year. During this time ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...